|
High risk neuroblastoma (HR-NB) with MNA and age <18 months: Results from the HR-NBL1/SIOPEN trial. |
|
|
Consulting or Advisory Role - Apeiron Biologics; Boehringer Ingelheim; EUSA Pharma (Inst) |
Research Funding - Apeiron Biologics (Inst); EUSA Pharma (Inst) |
Patents, Royalties, Other Intellectual Property - Apeiron Biologics (Inst); EUSA Pharma (Inst) |
Expert Testimony - Apeiron Biologics; EUSA Pharma |
|
|
No Relationships to Disclose |
|
Dominique Valteau Couanet |
Honoraria - Bellerophon Theraeutics |
Consulting or Advisory Role - EUSA Pharma (Inst) |
Research Funding - Orphelia Pharma (Inst) |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
Consulting or Advisory Role - Amgen; Novartis; Roche |
Travel, Accommodations, Expenses - Amgen; EUSA Pharma; Gilead Sciences; Jazz Pharmaceuticals; Takeda |
|
|
No Relationships to Disclose |
|
|
Stock and Other Ownership Interests - Xellera Therapeutics (Inst) |
Honoraria - Xellera Therapeutics (Inst) |
Consulting or Advisory Role - Xellera Therapeutics (Inst) |
Patents, Royalties, Other Intellectual Property - The University of Hong Kong (Inst) |
|
|
Travel, Accommodations, Expenses - EUSA Pharma |
|
|
No Relationships to Disclose |
|
|
|
Consulting or Advisory Role - EUSA Pharma |
Research Funding - EUSA Pharma (Inst); Roche Pharma AG (Inst) |
Travel, Accommodations, Expenses - EUSA Pharma |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
|
Travel, Accommodations, Expenses - SERVIER |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
|
Consulting or Advisory Role - Servier |
Research Funding - Bristol-Myers Squibb (Inst); MSDavenir (Inst); Pfizer (Inst); Roche (Inst) |
Travel, Accommodations, Expenses - EUSA Pharma; Roche; Roche |
|
|
Consulting or Advisory Role - EUSA Pharma |
Speakers' Bureau - EUSA PHarma |
Research Funding - EUSA Pharma (Inst) |
Travel, Accommodations, Expenses - EUSA PHARMA |